Product Benefits

• Targeted PBC Treatment: Obeliva 10mg (Obeticholic Acid) is specifically indicated for the treatment of Primary Biliary Cholangitis (PBC), a chronic liver disease that destroys bile ducts.

• Reduces Liver Enzyme Levels: Effectively lowers Alkaline Phosphatase (ALP) and bilirubin levels, which are key markers of liver stress and disease progression.

• Slows Disease Progression: By improving bile flow and reducing the accumulation of toxic bile acids in the liver, it helps slow the progression toward liver scarring and cirrhosis.

• Farnesoid X Receptor (FXR) Agonist: Works through a unique mechanism that regulates bile acid synthesis, transport, and metabolism, addressing the root cause of bile buildup.

• Second-Line Solution: Provides a critical therapeutic option for patients who do not respond adequately to Ursodeoxycholic Acid (UDCA) or those who cannot tolerate UDCA.

• Improves Liver Health: Helps protect liver cells (hepatocytes) from inflammation and autoimmune-mediated damage, supporting overall long-term organ function.

• Once-Daily Dosing: Designed for convenience with a simple once-a-day oral tablet, making it easier for patients to manage their chronic condition consistently.